SWP
ANIP icon

Stratos Wealth Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Stratos Wealth Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-53
Closed -$3K – 925
2018
Q3 		$3K Buy
+53
New +$3.24K ﹤0.01% 2586

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stratos Wealth Partners's ANIP Position: Q4 2018 in Review

Stratos Wealth Partners sold out of ANI Pharmaceuticals (ANIP) in Q4 2018, closing a stake of 53 shares — an estimated $3K sold.

Stratos Wealth Partners first reported a position in ANIP in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 170 funds tracked by Wall St. Rank hold ANIP as of Q4 2018.

  • Stratos Wealth Partners reported no remaining ANI Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 53 ANI Pharmaceuticals shares in Q4 2018, an estimated $3K.
  • Stratos Wealth Partners first reported a position in ANI Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Stratos Wealth Partners's ANI Pharmaceuticals position peaked at $3K in Q3 2018.
  • 170 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.